30 May 2013 
EMA/161384/2013 
Human Medicines Development and Evaluation 
Statement indicating compliance with the agreed completed 
paediatric investigation plan  
Medicinal product  
Glivec/ IMATINIB 
Pharmaceutical forms: 
See Annex A of the CHMP Opinion 
Strengths: 
Route of administration: 
See Annex A 
See Annex A 
Packaging and package sizes: 
See Annex A 
Numbers in the Community 
Register of Medicinal Products: 
See Annex A 
Marketing Authorisation Holder (MAH): 
Name and address of the MAH:  Novartis Europharm Ltd 
Wimblehurst Road 
Horsham 
West Sussex 
RH12 5AB 
UNITED KINGDOM 
Procedure  
Procedure number: 
EMEA/H/C/000406/II/0080 
Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and in 
accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that: 
• 
• 
the development of this product has complied with all measures in the agreed paediatric investigation 
plan P/0028/2012. For the purpose of the application of Article 45(3) of Regulation EC (No) 1901/2006, 
all studies in the agreed paediatric investigation plan P/0028/2012 were completed after the entry into 
force of that Regulation,  
the Summary of Product Characteristics adopted by CHMP reflects the results of studies conducted in 
compliance with this agreed paediatric investigation plan.  
7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom 
Telephone  +44 (0)20 7418 8400  Facsimile +44 (0)20 7418 8416 
E-mail info@ema.europa.eu  Website www.ema.europa.eu 
An agency of the European Union   
© European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
